Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy response.

Cancer Immunol Immunother

Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Published: March 2025

Background: T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) is a novel immune checkpoint playing a crucial role in immunosuppression and immune evasion. This study aims to elucidate the expression patterns, characteristics, and possible mechanisms of TIGIT in small cell lung cancer (SCLC).

Methods: TIGIT expression was analyzed across various cancers and normal tissues using The Cancer Genome Atlas (TCGA). Transcriptomic data from SCLC patients, sourced from the Gene Expression Omnibus (GEO) and literature, were analyzed to assess TIGIT-related characteristics. Immunohistochemistry (IHC) was used to verify TIGIT expression in post-surgical and advanced SCLC samples, focusing on expression characteristics, prognostic value, and treatment response.

Results: TIGIT was significantly overexpressed in various tumors, including SCLC (p < 0.05). Higher expression was associated with better overall survival (OS) (p < 0.05). Notably, a significant positive correlation was observed between TIGIT expression and immune-related metagenes, such as HCK, interferon, and LCK (p < 0.05). Immune infiltration analysis revealed a strong positive correlation between TIGIT expression and immune score in multiple cohorts. Additionally, TIGIT expression correlated positively with immune cells, including CD8 T cells, cytotoxic lymphocytes, and B cells (p < 0.05), and multiple immune checkpoints like BTLA, ICOS, and LAG3 (p < 0.05), while it had a significant negative correlation with the TIDE score (p < 0.05). In the validation section, patients with high TIGIT expression showed significantly prolonged disease-free survival (DFS) and OS (p < 0.05), and demonstrated a better response to adjuvant chemotherapy (ACT) and immunotherapy.

Conclusion: TIGIT serves as a biomarker in SCLC, with its high expression indicating favorable prognosis and treatment response. These effects may be due to TIGIT's unique immune landscape and its association with other immune checkpoints.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880484PMC
http://dx.doi.org/10.1007/s00262-025-03985-6DOI Listing

Publication Analysis

Top Keywords

small cell
8
cell lung
8
lung cancer
8
tigit expression
8
tigit
6
expression
5
exploring role
4
role tigit
4
tigit patients
4
patients small
4

Similar Publications

Non-small cell lung cancer (NSCLC) is a complex disease with diverse clinical and molecular characteristics. Since the discovery of the oncogenic neurotrophic receptor tyrosine kinase (NTRK) gene fusion in colorectal cancer in 1986, its understanding has gradually progressed. NTRK's relevance is crucial to understanding some tumor development and how specific tyrosine receptor kinase inhibitors (TRKI) work.

View Article and Find Full Text PDF

Background: The development of immunotherapy has led to a paradigm shift in the treatment of malignant tumors. Immune checkpoint inhibitors (ICIs) function by blocking the receptors and ligands of T cells from binding one another, empowering them to target and attack cancer cells. ICIs along with other immunotherapy treatments, have seen a significant increase in usage in recent years.

View Article and Find Full Text PDF

Background: This study conducted genetic analysis on fetuses indicated to be at high risk by non-invasive prenatal testing (NIPT) to explore the etiology.

Methods: Karyotype analysis and single nucleotide polymorphism array (SNP-array) were performed to detect copy number variations in fetal amniotic fluid and parental peripheral blood.

Results: Fetal karyotype showed 46, X?, del (4) (q28q31.

View Article and Find Full Text PDF

Direct Integration of Spent LiMnO with High Voltage Aqueous Zinc-Manganese Redox Flow Batteries as a Practical Upcycling Process.

Small

March 2025

Department of Nanoenergy Engineering, Pusan National University, 50, Busan daehak-ro 63 beon-gil 2, Busan, Geumjeong-gu, 46241, Republic of Korea.

With the explosive growth of lithium-ion batteries (LIBs), research on the recycling of spent batteries is widely conducted. However, conventional processes involve complex procedures, high costs, and environmental issues. This study introduces the electrochemical upcycling of spent LiMnO (LMO) cathode material, incorporating pre-filtration (PF) and pre-reduction (PR) processes to enable its direct application in redox flow batteries (RFBs).

View Article and Find Full Text PDF

Precise Control Over Crystallization Kinetics by Combining Nucleating Agents and Plasticizers for 20.1% Efficiency Organic Solar Cells.

Adv Mater

March 2025

National Engineering Research Center for Colloidal Materials, Key Laboratory of Special Functional Aggregated Materials (Shandong University), Ministry of Education, School of Chemistry & Chemical Engineering, Shandong University, Jinan, Shandong, 250100, China.

Obtaining controllable active layer morphology plays a significant role in boosting the device performance of organic solar cells (OSCs). Herein, a quaternary strategy, which incorporates polymer donor D18-Cl and small molecule acceptor AITC into the host D18:N3, is employed to precisely modulate crystallization kinetics for favorable morphology evolution within the active layer. In situ spectroscopic measurements during film-formation demonstrate that while D18-Cl works as a nucleator to promote aggregation of D18 and foster donor/acceptor intermixing, AITC has exactly the opposite impact on aggregation of N3 and intermixing kinetics of donor and acceptor, working as a plasticizer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!